Stock 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Zhejiang Ausun Pharmaceutical Co., Ltd. Stock

Equities

603229

CNE100002XK2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
10.49 CNY +0.87% Intraday chart for Zhejiang Ausun Pharmaceutical Co., Ltd. +9.84% -20.59%
04-26 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-26 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Financials

Sales 2024 * 1.16B 161M 220M Sales 2025 * 1.5B 207M 283M Capitalization 6.22B 859M 1.17B
Net income 2024 * 387M 53.41M 73.01M Net income 2025 * 517M 71.35M 97.54M EV / Sales 2024 * 5.34 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.14 x
P/E ratio 2024 *
16 x
P/E ratio 2025 *
12 x
Employees 1,129
Yield 2024 *
1.81%
Yield 2025 *
2.29%
Free-Float 40.03%
More Fundamentals * Assessed data

Chart Zhejiang Ausun Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Zhejiang Ausun Pharmaceutical Co., Ltd.

Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it has received CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd. CI
Ausun Pharma's Unit Passes Regulatory Inspection MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Qizheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Ausun Pharmaceutical Co., Ltd. CI
Zhejiang Ausun Pharma Sees Up to 70% Jump in 2022 Profit; Shares Rose 4% MT
Zhejiang Ausun Pharma Gets Regulatory Nod to Market Azvudine MT
Zhejiang Ausun Pharmaceutical Co., Ltd. announced that it has received CNY 484.90308 million in funding from Gongqingcheng Shengheng Investment Management Co., Ltd., Shanghai Panjing Investment Management Center (Limited Partnership), Taizhou Financial Holding Asset Management Co., Ltd., and other investors CI
Marvel Biosciences Completes Manufacturing Milestone Ahead of Phase 1 Trials Targeting Alzheimer's Disease, Depression MT
Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Ausun Pharmaceutical Co., Ltd.(XSSC:603229) added to S&P Global BMI Index CI
More news

Quotes and Performance

1 day+0.87%
1 week+9.84%
Current month+3.25%
1 month+1.16%
3 months-5.07%
6 months-22.24%
Current year-20.59%
More quotes

Highs and lows

1 week
9.48
Extreme 9.48
10.50
1 month
9.35
Extreme 9.35
10.84
Current year
8.06
Extreme 8.06
13.35
1 year
8.06
Extreme 8.06
17.47
3 years
8.06
Extreme 8.06
47.90
5 years
3.56
Extreme 3.5593
47.90
10 years
3.08
Extreme 3.0825
47.90
More quotes

Managers and Directors - Zhejiang Ausun Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Zhi Guo Zheng CEO
 Chief Executive Officer 53 14-12-14
Ding Min Zhu DFI
 Director of Finance/CFO 57 21-11-01
Hua Dong Zhang BRD
 Director/Board Member 47 14-12-13
Members of the board TitleAgeSince
Fei Chen BRD
 Director/Board Member 44 15-01-07
Zhi Guo Zheng CEO
 Chief Executive Officer 53 14-12-14
Zhi Shu Yang BRD
 Director/Board Member 58 20-12-12
More insiders

ETFs positioned on Zhejiang Ausun Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Zhejiang Ausun Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
24-04-26 10.49 +0.87% 4,548,732
24-04-25 10.4 +3.07% 5,357,286
24-04-24 10.09 +1.00% 2,873,756
24-04-23 9.99 +0.60% 5,152,012
24-04-22 9.93 +3.98% 6,445,888

End-of-day quote Shanghai S.E., April 25, 2024

More quotes

Company Profile

Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
Sector
Pharmaceuticals
Calendar
2024-08-27 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Ausun Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.49
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Ausun Pharmaceutical Co., Ltd.
-20.59% 859M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603229 Stock